Devonian Health Group, Inc. (TSE:GSD) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Devonian Health Group reported a significant 360% increase in first-quarter revenues, boosted by the success of its Altius subsidiary’s pharmaceutical product, DEXLANSOPRAZOLE. Despite the revenue surge, the company posted a net loss of $0.002 per share. Additionally, Devonian granted over 1.5 million stock options to its independent directors, signaling confidence in future growth.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue